The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
NORCROSS, Ga., Jan. 30, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D, president, chief executive officer and chief medical officer, will present live at VirtualInvestorConferences.com on February 2, 2017.
DATE: Thursday, February 2, 2017
TIME: 11:30 am EST
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
About Galectin Therapeutics Inc.
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Galectin Therapeutics Inc.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2017/30/c1191.html
For further information: Galectin Therapeutics Inc., Jack Callicutt, Chief Financial Officer, (678) 620-3186, email@example.com ; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org, http://galectintherapeutics.com